Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.

Devices and Getinge have recently announced their partnership under which they will integrate Getinge’s bioreactors with 908 ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

The US Food and Drug Administration (FDA) is cautioning patients and caregivers about the potential for not receiving blood ...

How the UAE uses AI-enabled medical care to better the lives of patients and optimises efficiencies in medicine with AI ...

The FDA today issued an alert around a safety concern regarding diabetes devices that rely on smartphones to deliver critical safety alerts.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for ...

The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...